• Native and Derivative Cyclodextrins trappsol

    Used in R & D and specialty manufacturing

    Read more
  • Cyclodextrin Complexes aquaplex

    Improves ingredient solubility for food, nutritional and pharmaceutical formulations

    Read more
  • API Grade Cyclodextrins trappsol cyclo

    Cyclodextrins as active pharmaceutical ingredients

    Read more

CTD Holdings Announces Approval of Clinical Trial Application to Conduct Phase I/II Clinical Study of Trappsol(R) Cyclo(TM) in Patients with Niemann-Pick Type C Disease at Karolinska University Hospital

Karolinska Represents Third Approved Study Site in Europe; First Patient Expected to be Enrolled in Phase I/II Study in First Quarter of 2017

ALACHUA, FL -- (Marketwired) -- 11/10/16 -- CTD Holdings, Inc. (OTCQB: CTDH), a biotechnology company developing cyclodextrin-based products for the treatment of diseases with unmet medical need, today announced that the Swedish Medical Products Agency has approved CTD Holdings' Clinical Trial Application to conduct a Phase I/II clinical study at Karolinska University Hospital in Sweden evaluating Trappsol® Cyclo™ in patients with Niemann-Pick Type C (NPC) Disease, a rare and fatal illness tied to an autosomal recessive genetic defect. Karolinska represents the third site in Europe approved to conduct this study. CTD Holdings expects that the first patient in this Phase I/II clinical trial will be dosed in the first quarter of 2017.

Trappsol® Cyclo™ is a parenteral grade of hydroxypropyl beta cyclodextrin, a donut-shaped molecule comprised of seven glucopyranose units. Its hydrophilic exterior allows it to move easily through the body, and its inner hydrophobic cavity allows it to capture and hold certain types of molecules. To date, intravenous Trappsol® Cyclo™ has been administered to 21 NPC patients worldwide, some for more than five years, via multiple Compassionate Use Programs. During this time, multiple patients have shown marked improvements in neurological symptoms, lung function or liver morphology, or had stabilization of disease progression, with no significant, unexpected, safety concerns.

"We view this third site approval at such a prestigious institution in Europe, Karolinska University Hospital, as validation of the potential of intravenous Trappsol® Cyclo™ in treating NPC," said N. Scott Fine, Chief Executive Officer of CTD Holdings. "In addition to the Phase I/II study we are conducting in Europe, we also expect to begin enrolling patients in a U.S. Phase I study to evaluate the safety and impact of intravenous Trappsol® Cyclo™ on biomarkers of NPC Disease in the first quarter of 2017. NPC is a highly under-served orphan disease with an addressable market of over $400 million, and represents a significant opportunity for CTD Holdings."

"NPC is a fatal disease that is difficult to diagnose and is consequently under-diagnosed," said Dr. Sharon Hrynkow, CTD's Senior VP for Medical Affairs. "There is currently only one approved treatment for the disease in Europe, and none in the U.S. Based on the Compassionate Use Program data garnered to date, we believe Trappsol® Cyclo™ administered intravenously has the potential to effectively treat NPC. We look forward to working with our colleagues in Sweden to further evaluate this promising drug candidate in this Phase I/II study."

CTD Holdings received Orphan Drug designation for the use of Trappsol® Cyclo™ in NPC from the U.S. Food and Drug Administration and the European Medicines Agency.

For further information on this trial and the U.S. trial, please visit www.ClinicalTrials.gov.

Recent News:

  • Feb 23 2017, 7:53 AM EST CTD Holdings Closes $2 Million Private Placement
  • Feb 16 2017, 8:00 AM EST CTD Holdings Presents Compassionate Use Data on Trappsol(R) Cyclo(TM) to Treat Niemann-Pick Disease Type C and Provides Update on Progress of U.S. and EU Clinical Trials at 13th Annual WORLDSymposium
  • Jan 17 2017, 8:00 AM EST CTD Holdings Receives FDA Fast Track Designation for Development of Trappsol(R) Cyclo(TM) to Treat Niemann-Pick Disease Type C